Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lapatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 17/20 | 0.97 |
| ▸ | ERBB2 known ✓ | P04626 | 14/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.97 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.97 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.97 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.97 |
| ▸ | STK10 | O94804 | 1/20 | 0.97 |
| ▸ | ABL1 | P00519 | 1/20 | 0.97 |
| ▸ | INSR | P06213 | 1/20 | 0.97 |
| ▸ | RET | P07949 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.97 |
| ▸ | SRC | P12931 | 1/20 | 0.97 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.97 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.97 |
| ▸ | CDK2 | P24941 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lapatinib SCHEMBL2505835 | 1.00 | EGFR (0.97) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL15971863 | 0.99 | EGFR (0.96) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL2505075 | 0.99 | EGFR (0.96) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL2501563 | 0.99 | EGFR (0.96) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL3233815 | 0.99 | EGFR (0.96) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL29464189 | 0.99 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL16766960 | 0.99 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL29351024 | 0.99 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL8100 | 0.99 | EGFR (1.00) | EGFRERBB2ABCB11MEN1PIK3C2B | |
| Lapatinib SCHEMBL4924110 | 0.98 | EGFR (0.99) | EGFRERBB2ABCB11MEN1PIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115715764-B | Apatinib oral patch and preparation method thereof | 北京理工大学 | 2024-06-25 | — | — | CN | disclosed |
| CN-114366748-A | Crystalline solid forms of BET inhibitors | 因赛特公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-114369091-A | Crystalline solid forms of BET inhibitors | 因赛特公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-109715625-B | Crystalline solid forms of BET inhibitors | 因赛特公司 | 2022-04-19 | — | — | CN | disclosed |
| US-20220054475-A1 | USING CATEQUENTINIB (ANLOTINIB) COMBINING WITH STANDARD CHEMOTHERAPY OR IMMUNOTHERAPY IN SEQUENTIAL ORDER FOR THE CANCER TREATMENT | ADVENCHEN PHARMACEUTICALS LLC (US) | 2022-02-24 | — | — | US | disclosed |
| EP-3934645-A1 | USING CATEQUENTINIB (ANLOTINIB) COMBINING WITH STANDARD CHEMOTHERAPY OR IMMUNOTHERAPY IN SEQUENTIAL ORDER FOR THE CANCER TREATMENT | Advenchen Pharmaceuticals LLC (US) | 2022-01-12 | — | — | EP | disclosed |
| CN-113769097-A | Use of EGFR/HER2 inhibitor in combination with pyrimidine antimetabolites | 江苏恒瑞医药股份有限公司 | 2021-12-10 | — | — | CN | disclosed |
| CN-113518621-A | Sequential use of a combination of carquinitinib (Arotinib) and standard chemotherapy or immunotherapy for the treatment of cancer | 南京爱德程医药科技有限公司 | 2021-10-19 | — | — | CN | disclosed |
| EP-3153169-B1 | METHOD FOR TREATING TUMOUR, PHARMACEUTICAL COMPOSITION AND MEDICINE BOX KIT | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2020-08-05 | — | — | EP | disclosed |
| CN-105311030-B | Anti-tumor spiro-substituted compound | 正大天晴药业集团股份有限公司 | 2020-03-24 | — | — | CN | disclosed |
| US-20190358212-A1 | USES OF EGFR/HER2 INHIBITOR COMBINED WITH PYRIMIDINE-TYPE ANTI-METABOLIC DRUG | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-11-28 | — | — | US | disclosed |
| US-20190269671-A1 | METHOD FOR TREATING TUMOUR, PHARMACEUTICAL COMPOSITION AND MEDICINAL KIT | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2019-09-05 | — | — | US | disclosed |
| US-10251876-B2 | Method for treating tumour, pharmaceutical composition and medicinal kit | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2019-04-09 | — | — | US | disclosed |
| US-20170182027-A1 | METHOD FOR TREATING TUMOUR, PHARMACEUTICAL COMPOSITION AND MEDICINAL KIT | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2017-06-29 | — | — | US | disclosed |
| EP-3153169-A1 | METHOD FOR TREATING TUMOUR, PHARMACEUTICAL COMPOSITION AND MEDICINE BOX KIT | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2017-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054475-A1 | USING CATEQUENTINIB (ANLOTINIB) COMBINING WITH STANDARD CHEMOTHERAPY OR IMMUNOTHERAPY IN SEQUENTIAL ORDER FOR THE CANCER TREATMENT | CXCL8, WEE1, PDCD1 | EGFR 247/4885ERBB2 259/4885ABCB11 2809/4885 |
| US-20170182027-A1 | METHOD FOR TREATING TUMOUR, PHARMACEUTICAL COMPOSITION AND MEDICINAL KIT | KIT, VIP, INMT | EGFR 1147/4885ERBB2 209/4885ABCB11 703/4885 |
| US-10251876-B2 | Method for treating tumour, pharmaceutical composition and medicinal kit | KIT, VIP, INMT | EGFR 1147/4885ERBB2 209/4885ABCB11 703/4885 |
| US-20190269671-A1 | METHOD FOR TREATING TUMOUR, PHARMACEUTICAL COMPOSITION AND MEDICINAL KIT | KIT, VIP, INMT | EGFR 1147/4885ERBB2 209/4885ABCB11 703/4885 |
| US-20190358212-A1 | USES OF EGFR/HER2 INHIBITOR COMBINED WITH PYRIMIDINE-TYPE ANTI-METABOLIC DRUG | ERBB2, EGFR, DPYD | EGFR 2/4885ERBB2 1/4885ABCB11 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.